Edition:
India

Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

12.31CAD
16 Aug 2019
Change (% chg)

$3.33 (+37.08%)
Prev Close
$8.98
Open
$9.98
Day's High
$13.57
Day's Low
$9.11
Volume
112,814
Avg. Vol
12,557
52-wk High
$720.00
52-wk Low
$7.13

Latest Key Developments (Source: Significant Developments)

Prometic Life Sciences Q2 Revenue C$8.8 Million
Tuesday, 13 Aug 2019 

Aug 12 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2019.Q2 REVENUE C$8.8 MILLION VERSUS C$20.2 MILLION.EFFECTIVE SEPTEMBER 1, 2019, MURIELLE LORTIE, CURRENTLY VICE PRESIDENT - FINANCE, WILL BE PROMOTED TO CFO OF COMPANY.  Full Article

Prometic Life Sciences Says Kenneth Galbraith Appointed CEO
Tuesday, 23 Apr 2019 

April 23 (Reuters) - Prometic Life Sciences Inc ::PROMETIC COMPLETES REFINANCING TRANSACTIONS INCLUDING C$75 MILLION (APPROXIMATELY US$56 MILLION) IN GROSS PROCEEDS FROM NEW EQUITY FINANCING.PROMETIC LIFE SCIENCES INC - STEFAN CLULOW APPOINTED AS CHAIR OF BOARD.PROMETIC LIFE SCIENCES INC - KENNETH GALBRAITH APPOINTED AS CHIEF EXECUTIVE OFFICER.PROMETIC LIFE SCIENCES INC - SIMON BEST HAS BEEN APPOINTED PROMETIC'S LEAD INDEPENDENT DIRECTOR.  Full Article

Prometic Announces Refinancing Transactions
Monday, 15 Apr 2019 

April 15 (Reuters) - Prometic Life Sciences Inc ::PROMETIC ANNOUNCES REFINANCING TRANSACTIONS.PROMETIC LIFE SCIENCES INC - ENTERED INTO DEFINITIVE AGREEMENTS TO COMPLETE AN EQUITY OFFERING FOR GROSS PROCEEDS OF $75 MILLION.PROMETIC LIFE SCIENCES INC - PRIVATE PLACEMENT WILL CONSIST OF ISSUANCE, ON A PRIVATE PLACEMENT BASIS, OF 4.93 BILLION COMMON SHARES.PROMETIC LIFE SCIENCES INC - CONSONANCE HAS AGREED TO SUBSCRIBE FOR $50 MILLION OF COMMON SHARES.PROMETIC LIFE SCIENCES INC - SALP HAS AGREED TO SUBSCRIBE FOR $25 MILLION OF ADDITIONAL COMMON SHARES IN PRIVATE PLACEMENT.PROMETIC LIFE SCIENCES INC - NEGOTIATED CONVERSION OF ABOUT $229 MILLION OF OUTSTANDING DEBT OF PROMETIC OWNED BY STRUCTURED ALPHA LP INTO COMMON SHARES.  Full Article

Prometic Reports Q4 Net Loss Of $141.3 Mln
Tuesday, 2 Apr 2019 

April 1 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS FOURTH QUARTER AND 2018 YEAR-END FINANCIAL RESULTS.Q4 REVENUE C$10.6 MILLION VERSUS C$6.6 MILLION.PROMETIC LIFE SCIENCES - INCURRED A NET LOSS OF $141.3 MILLION DURING QUARTER VERSUS NET LOSS OF $41.6 MILLION FOR CORRESPONDING PERIOD OF 2017.NEAR-TERM FINANCING SHORTFALL REQUIRES URGENT ACTION TO RESTRUCTURE CORPORATION'S INDEBTEDNESS AND RAISE CAPITAL.  Full Article

Simon Best Appointed Interim CEO Of Prometic Life Sciences
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Prometic Life Sciences Inc ::PROF. SIMON BEST APPOINTED INTERIM CEO OF PROMETIC LIFE SCIENCES.PROMETIC LIFE SCIENCES INC - BEST HAS BEEN CHAIRMAN OF PROMETIC BOARD OF DIRECTORS SINCE MAY 2014.PROMETIC LIFE SCIENCES INC -APPOINTING A TIER GLOBAL SEARCH FIRM TO COMMENCE SEARCH FOR A PERMANENT CEO.PROMETIC LIFE SCIENCES - ZACHARY NEWTON APPOINTED TO BOARD AS SECOND DESIGNEE OF STRUCTURED ALPHA LP, AN AFFILIATE OF THOMVEST ASSET MANAGEMENT.PROMETIC LIFE SCIENCES - BEST SUCCEEDS PIERRE LAURIN WHO HAS STEPPED DOWN FROM HIS MANAGEMENT AND BOARD RESPONSIBILITIES, EFFECTIVE IMMEDIATELY.  Full Article

Prometic Reports Third Quarter 2018 Financial Results
Thursday, 15 Nov 2018 

Nov 14 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS.Q3 REVENUE C$12.3 MILLION.PROMETIC LIFE SCIENCES- INCURRED A NET LOSS OF $28.9 MILLION FOR Q3 ENDED SEPTEMBER 30, 2018 COMPARED TO A NET LOSS OF $17.8 MILLION FOR Q3 2017.  Full Article

Prometic Announces Extension Of Debt Maturities To 2024
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Prometic Life Sciences Inc ::PROMETIC ANNOUNCES EXTENSION OF DEBT MATURITIES TO 2024.PROMETIC LIFE SCIENCES - SIGNED LOI WITH STRUCTURED ALPHA TO EXTEND MATURITY DATES OF $80 MILLION LINE OF CREDIT AND ORIGINAL ISSUE DISCOUNT NOTES.  Full Article

Prometic Life Sciences Incurred Net Loss Of $34.6 Mln For Quarter
Wednesday, 16 May 2018 

May 15 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS ITS 2018 FIRST QUARTER HIGHLIGHTS AND FINANCIAL RESULTS.PROMETIC LIFE SCIENCES INC - TOTAL REVENUES FOR Q1 ENDED MARCH 31, 2018 WERE $4.3 MILLION COMPARED TO $4.9 MILLION FOR Q1 ENDED MARCH 31, 2017.PROMETIC LIFE SCIENCES INC - CORP INCURRED NET LOSS OF $34.6 MILLION FOR QUARTER VERSUS A NET LOSS OF $29.1 MILLION.  Full Article

Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 Trial
Monday, 30 Apr 2018 

April 30 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS POSITIVE CLINICAL DATA FROM ITS INTRAVENOUS IMMUNOGLOBULIN (IVIG) PIVOTAL PHASE 3 TRIAL.PROMETIC LIFE SCIENCES INC - PIVOTAL CLINICAL TRIAL MEETS PRIMARY AND SECONDARY ENDPOINTS.PROMETIC LIFE SCIENCES INC - CLINICAL DATA DEMONSTRATES COMPARABLE EFFICACY TO COMMERCIALLY-APPROVED DRUG.PROMETIC LIFE SCIENCES INC - PROMETIC IVIG'S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES.PROMETIC LIFE SCIENCES INC - PROMETIC IVIG'S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES.PROMETIC LIFE SCIENCES INC - OVERALL PROMETIC IGIV 10% APPEARED TO BE WELL TOLERATED AND WAS NOT ASSOCIATED WITH ANY SBIS.  Full Article

Prometic reports positive interim clinical data from IVIG phase 3 trial
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Prometic Life Sciences Inc :Prometic reports positive interim clinical data from ongoing intravenous immunoglobulin (IVIG) pivotal phase 3 trial.Prometic Life Sciences Inc - ‍interim clinical data shows non inferiority to commercially-approved products for primary immunodeficiencies​.Prometic Life Sciences - ‍clinical data confirmed no significant safety issues, efficacy appeared to be comparable to existing commercial IVIG products​.  Full Article